Positive news for our portfolio company, Oxford BioTherapeutics, it has announced a research collaboration with Kite, the global leader in cell therapy to evaluate five novel targets for a number of hematologic and solid tumor indications.
- Investing With Us
Growth EIS - Investor
Invest in the future of UK technology
Growth EIS - Adviser
Build a portfolio of shares in the future of UK technology
Co-Investor Circle
Invest directly into single companies.
Family Offices
Co-Investing With Oxford Capital
Business Relief
Receive tax relief from EIS investments
More Information:
- Seeking Investment
Pre-Seed Investors
Get pre-seed investment through the EIS.
Seed Investors
Get seed investment through the EIS.
Cyber Security Investors
Investing in a safer digital future.
Digtial Health Investors
Investing in a healthier future.
Fintech Investors
Bringing new talent to financial services.
Retail Tech Investors
Investing in disruptive retail tech across the UK
More Information:
- About Us
About Us
Learn more about us
Our Investment Approach
Find our more about our approach to investment.
Our Portfolio
Browse our portfolio
Our Team
Meet our team
FAQs
See our frequently asked questions
- Resources
Introduction to EIS
Learn more
EIS Loss Relief Guide
Learn more
EIS Income Tax Relief
Learn more
EIS vs VCTs
Learn more
Is EIS a good investment?
Learn More
Are EIS Tax Free?
Learn More